

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Currently amended) A method of treating ~~or preventing~~ a myelodysplastic syndrome, which comprises administering to a patient having myelodysplastic syndrome in need of such treatment or prevention a therapeutically ~~or prophylactically~~ effective amount of ~~a selective cytokine inhibitory drug~~ cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isindol-4-yl}-amide, or a pharmaceutically acceptable salt, solvate, ~~hydrate, or~~ stereoisomer, ~~elathrate, or prodrug~~ thereof.

3. (Currently amended) ~~A~~ The method of claim 1 ~~treating or preventing a myelodysplastic syndrome, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a selective cytokine inhibitory drug or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, elathrate, or prodrug thereof; and further comprising~~ a therapeutically ~~or prophylactically~~ effective amount of at least one second active ingredient.

4. (Canceled)

5. (Currently amended) The method of claim 3 ~~or 4~~, wherein the second active ingredient is capable of improving blood cell production.

6. (Currently amended) The method of claim 3 ~~or 4~~, wherein the second active ingredient is a cytokine, hematopoietic growth factor, anti-cancer agent, antibiotic, proteasome inhibitor, or immunosuppressive agent.

7. (Currently amended) The method of claim 3 ~~or 4~~, wherein the second active ingredient is etanercept, imatinib, anti-TNF- α antibodies, infliximab, G-CSF, GM-CSF, EPO, topotecan, pentoxifylline, ciprofloxacin, irinotecan, vinblastine, dexamethasone, IL2, IL8,

IL18, Ara-C, vinorelbine, isotretinoin, 13-cis-retinoic acid, or a pharmacologically active mutant or derivative thereof.

8. (Currently amended) The method of ~~any one of claims 1 to 4~~ or 3, wherein the myelodysplastic syndrome is refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or chronic myelomonocytic leukemia.

9. (Currently amended) The method of ~~any one of claims 1 to 4~~ or 3, wherein the myelodysplastic syndrome is primary or secondary.

10-12. (Canceled)

13. (Currently amended) The method of ~~any one of claims 1 to 4~~ or 3, wherein the ~~selective cytokine inhibitory drug is~~ stereoisomer of cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 *H*-isoindol-4-yl}-amide is S enantiomer.

14. (Original) The method of claim 1 or 3 [[13]] wherein the ~~selective cytokine inhibitory drug is the R or S enantiomer of~~ stereoisomer of cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 *H*-isoindol-4-yl}-amide is R enantiomer.

15-37. (Canceled)

38. (New) The method of claim 1, wherein the compound or a pharmaceutically acceptable salt, solvate or stereoisomer thereof is administered before, during or after transplanting umbilical cord blood, placental blood, peripheral blood stem cell, hematopoietic stem cell preparation or bone marrow in the patient.

39. (New) The method of claim 3, wherein the second active ingredient is dexamethasone.

40. (New) The method of claim 1, wherein the patient has not been previously

treated for a myelodysplastic syndrome.

41. (New) The method of claim 1, wherein the patient has been previously treated for a myelodysplastic syndrome.

42. (New) The method of claim 1, wherein the compound or a pharmaceutically acceptable salt, solvate or stereoisomer thereof is administered orally.

43. (New) The method of claim 1, wherein the compound or a pharmaceutically acceptable salt, solvate or stereoisomer thereof is administered in the form of a capsule or tablet.

44. (New) The method of claim 1, wherein the compound or a pharmaceutically acceptable salt, solvate or stereoisomer thereof is administered cyclically.

45. (New) The method of claim 44, wherein the compound or a pharmaceutically acceptable salt, solvate or stereoisomer thereof is administered on days 1-21 every 28 days.

46. (New) The method of claim 44, wherein one cycle comprises the administration of the compound and at least one, two, or three weeks of rest.

47. (New) The method of claim 46, wherein the number of cycle is from one to twelve cycles.

48. (New) The method of claim 44, wherein the compound or a pharmaceutically acceptable salt, solvate or stereoisomer thereof is administered in an amount of from about 10 mg to about 2500 mg per day on days 1-21 every 28 days.

49. (New) The method of claim 48, wherein the compound or a pharmaceutically acceptable salt, solvate or stereoisomer thereof is administered in an amount of from about 100 mg to about 800 mg per day on days 1-21 every 28 days.

50. (New) The method of claim 1, wherein the solvate is a hydrate.